Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 2,700 Shares

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $109.66, for a total value of $296,082.00. Following the transaction, the insider now directly owns 304,508 shares of the company’s stock, valued at $33,392,347.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $108.30, for a total value of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The shares were sold at an average price of $92.47, for a total value of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The shares were sold at an average price of $90.22, for a total value of $40,328.34.

Natera Stock Up 0.0 %

Natera stock opened at $111.39 on Thursday. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $117.23. The business has a 50-day moving average of $103.60 and a 200-day moving average of $85.10. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. The company had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company’s revenue for the quarter was up 52.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.23) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -2.43 EPS for the current year.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the stock. DekaBank Deutsche Girozentrale bought a new position in shares of Natera during the 1st quarter valued at about $83,000. Cetera Advisors LLC bought a new position in shares of Natera during the 1st quarter valued at about $442,000. Cetera Investment Advisers lifted its holdings in shares of Natera by 514.9% during the 1st quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company’s stock valued at $1,802,000 after purchasing an additional 16,496 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Natera by 13.0% during the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after purchasing an additional 452,800 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Natera during the 1st quarter valued at about $707,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NTRA. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. BTIG Research raised their target price on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, May 13th. The Goldman Sachs Group raised their target price on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Finally, Canaccord Genuity Group raised their target price on Natera from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, May 10th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.